In human ovarian cancer, Peng et al. [77] found that inhibitors of DNMT1 and EZH2 reactivate the production of T helper 1 (TH1)-type chemokines (CXCL9 and CXCL10), increase effector T-cell tumor infiltrations, slow down the tumor progression and improve the therapeutic efficacy of anti-PD-L1. Here, EZH2 is linked to neoplasm.